Bladder cancer (BC) is the fifth most common malignancy in the general population and its incidence increases with age, which represents the most significant risk factor for it. Men are predominantly affected, with a 3 : 1 male:female ratio ([@bib19]). A wide range of environmental risk factors has been identified among which are tobacco smoking, consumption of arsenic-contaminated water, occupational exposure to aromatic amines and polycyclic hydrocarbons, and chronic infection with Schistosoma species ([@bib26]). Several germline variants have also been recognised as contributors to BC risk ([@bib13]).

At diagnosis, the majority of BC are non-muscle invasive (80%, Stage Ta-T1; NMIBC) and only 20% of all diagnosed BC cases are muscle-invasive (Stage T2 and above; MIBC). Despite endovesical treatment, NMIBCs frequently recur (50--70%) and sometimes progress to detrusor muscle invasion (10--15% [@bib37]). Cystoscopy is the most used way to monitor these patients who frequently undergo multiple endoscopic resections over the years. Risk tables provide a prognostic tool regarding the risk of recurrence and progression of NMIBC, whereas the prognosis of MIBC patients is less favourable due to a high risk of metastatic progression, independently of treatment. Up-to-date, there are no molecular biomarkers to accurately predict disease progression ([@bib36]).

As for many other cancers, also for BC there is an established variation of individual susceptibility that may be modulated by interaction of environmental exposures and genetic factors. Biologic variability may occur at any stage of carcinogenesis; therefore, variation in inter-individual susceptibility poses a challenge in quantitative human risk assessment and warrants testing and validation of biomarkers that allow accurate identification of high-risk individuals. Evidence that cytogenetic biomarkers are positively correlated with cancer risk has been strongly validated in both cohort and nested case-control studies, leading to the conclusion that chromosome aberrations are a relevant marker of cancer risk ([@bib8]), which reflects the outcome of both the genotoxic effects of carcinogens and the genetic host susceptibility. The cytokinesis-block micronucleus (CBMN) assay is a relatively fast and easy technique extensively used in molecular epidemiology and cytogenetics. The assay is applied to evaluate the presence and the extent of chromosomal damage in populations exposed to genotoxic agents or in case of the presence of a susceptible genetic profile in several cell types, including newly divided peripheral blood mononuclear cells (PBMC; [@bib7]). The measurement of micronucleus (MN) frequency in PBMC has also been applied for the identification of dietary and genetic factors with a significant impact on genome stability. The high reliability and low cost of the CBMN technique has contributed to its success worldwide and to the adoption for *in vitro* and *in vivo* studies of genome damage ([@bib7]). Similarly to other *in vitro* cytogenetic assays, there is a known inter- and intra-laboratory variability. However, there are still limited information on the effects of the laboratory method, subject lifestyle and the role of individual susceptibility on this variability. The long-term health significance of PBMC MN is also a major issue to be clarified. The International Human Micronucleus (HUMN) Project ([www.humn.org](http://www.humn.org)) was created in this sense to coordinate worldwide research efforts aimed at using CBMN assays to study DNA damage in human populations and to establish standardised protocols so that data comparisons can be made more reliably across laboratories and countries ([@bib17]).

The origin of MN is from whole chromosomes not included in the main daughter nuclei or from chromosome fragments that are lost during nuclear division. In dividing cells, the formation of MN derives from chromosome malsegregation due to mitotic malfunction or from unrepaired/misrepaired DNA lesions that generate chromosome breakage. The events described may be induced by several factors including oxidative stress, exposure to clastogens or aneugens, various genetic defects involving malfunctions of the cell cycle checkpoints and/or DNA repair, as well as deficiencies of nutrients important as cofactors for the metabolism of DNA and for the machinery of chromosome segregation ([@bib16]). Therefore, the CBMN assay can be considered a possible test to evaluate the level of DNA damage in the cells.

In the present study, we evaluated whether MN frequency as detected by the CBMN assay can be used as a potential molecular biomarker to identify individuals with increased risk of BC, recurrence or progression in a large hospital-based case-control study (158 cases and 158 controls matched for gender (all males), age and smoking habits). The assay was performed on cryopreserved PBMC. Additionally, the distribution of genotypes of a large number of polymorphisms in DNA repair genes among cases (NMIBC) and controls and their associations with the frequencies of the analysed CBMN end points were investigated.

Materials and methods
=====================

Study population
----------------

The study population included newly diagnosed, histologically confirmed cases of BC included in the Turin Bladder Cancer Study ([@bib31]; [@bib30]). Controls were men recruited during the same period as cases in random fashion from patients treated at the same urology departments for non-neoplastic disease or from patients treated at the medical and surgical departments for various problems (hernias, vasculopathies, diabetes, heart failure, asthma or other benign diseases). Detailed description of the study population is given in the [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}. All subjects were informed and provided written informed consent according to the Helsinki declaration. The design of the study was approved by the local Ethics Committees.

Isolation and storing of lymphocytes
------------------------------------

The isolation and storing of lymphocytes was described in [@bib38]). A more detailed description of the process is given in the [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Cytokinesis-block micronucleus assay
------------------------------------

Cryopreserved PBMC from 158 cases (collected before treatment) and 158 controls matched by age (±1 year) and smoking habits, were selected from the Turin Bladder Cancer Study collection and processed for the CBMN assay.

Cell lymphocytes cultures were set up according to [@bib45]). A detailed description of the assay is given in the [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}. For each blood sample at least two cultures were set up in round-bottomed tissue cultures tubes. For each experiment 7--8 samples were processed.

For each subject, 1000 binucleated cells were scored from untreated cultures (500 cells from each of two cultures). Scoring of binucleated cells with MN, nucleoplasmic bridges (NPB) and nuclear buds (NBUD) was performed by two independent scorers following the criteria developed by [@bib16]. Cell proliferation was evaluated determining the nuclear division index in 500 cells. Nuclear division index was calculated as follows: (M1+2M2+3M3+4M4)/*N*, where M1--M4 represent the number of cells with 1--4 nuclei respectively, and *N* is the total number of viable cells scored.

Genotyping and quality controls
-------------------------------

DNA was isolated from PBMC with the Qiagen DNeasy blood and tissue kit (Qiagen, Milan, Italy) according to the manufacturer\'s protocol.

Whole-genome genotyping was performed on an Illumina HumanOmniExpressExome-8 v1.2 (containing 964193 single nucleotide polymorphisms (SNPs)) for 306 subjects. Genotypes were assessed by GenomeStudio V2011.1 (Illumina, San Diego, CA, USA).

A cut-off for a genotyping call rate of 0.90 was set, leading to the exclusion of three study subjects. The identity by descent estimation was used to check relatedness among subjects (R 3.0.3, SNPRelate package). Subjects with kinship coefficient \>0.0625 (two couples) were considered consanguineous and excluded (one per couple) from further analyses. Population structure was investigated through Principal Component Analysis: two outlier subjects were found and then removed, leaving 299 subjects (152 cases and 147 controls).

SNPs having \>5% missing genotypes (*n*=7854), deviating from Hardy--Weinberg equilibrium (*P*\<0.0001, *n*=378) or with minor allele frequency \<5% (*n*=339,031) were excluded from the analysis, for a final study data set of 616454 SNPs. From 5412 SNPs in DNA repair genes present in the Illumina HumanOmniExpressExome-8 v1.2 BeadChip (<http://sciencepark.mdanderson.org/labs/wood/dna_repair_genes.html> for the complete list of genes involved in different DNA repair pathways), 1457 passed the above described filters. Among them, 783 were selected after linkage disequilibrium analysis (R 3.0.3, SNPRelate package, linkage disequilibrium threshold⩾0.8) and analysed for their distribution among cases and controls and for their potential association with CBMN frequencies.

Statistical analysis
--------------------

All the analyses were performed with the open source R (R 3.1.0). The influence of possible explicative variables on the frequency of MN, NBUD and NPB was evaluated by multivariate analysis and/or non-parametric statistical hypothesis test, since variables did not follow a normal distribution (by Shapiro--Wilk normality test).

The Wilcoxon rank sum test was applied to compare the distribution of MN, NBUD and NPB between groups. Correlation analysis and Kruskal--Wallis rank sum test were also performed to estimate associations among independent variables (smoking habits, age, batch effect, etc).

Overall survival was evaluated calculating the time (in months) between the date of BC diagnosis and the date of death or follow up termination as the end point for each patient. Event-free survival was calculated as the time (in months) between the date of BC diagnosis until date of relapse, death or censorship, whichever came first. The relative risk of death or of recurrence/progression against each of the 3 CBMN end points was estimated as hazard ratios using unadjusted Cox regression (R 3.0.3, Survival package). MN, NBUD and NPB were all considered continuous or categorical; multivariate survival analyses were adjusted for matching variables, risk category and therapy for the whole group of patients. The prognostic role of CBMN end points on survival was also evaluated using Kaplan Meier curves and log-rank test. In the best fitted model survival analyses, hazard ratios were calculated by multivariate Cox regression, satisfying their proportional hazards (PH) assumptions.

The distribution of genotypes of selected DNA repair variants among NMIBC cases and controls was evaluated in two steps, first by *χ*^2^ Test followed by regression analysis, adjusting for age and smoking habits.

The genotype influence on the frequency of micronucleated per 1000 binucleated cells was assessed by Kruskal--Wallis rank sum test only on NMIBC and in the same way as described above and then confirmed by regression analysis, adjusted for the same match variables.

Finally, different prediction models were built to evaluate the diagnostic power of investigated markers: (1) a model including age and smoking status (model A); (2) model A with the additional predictor SNPs with different genotype frequencies among cases and controls (model B); (3) model B with the inclusion of MN frequencies (model C). Discrimination analysis was conducted comparing the area under receiver operating characteristic (ROC) curve of the three nested models by the DeLong\'s test (pROC package).

Results
=======

Study population
----------------

The study included PBMC from 158 cases and 158 controls matched by age and smoking habits. For 10 controls and six cases, technical problems were encountered (i.e., slides were not scorable or the number of counted binucleated cells was not sufficient). Since no additional aliquots of cryopreserved PBMC were available these subjects were excluded from the analysis. Finally, 152 newly diagnosed, previously untreated males BC patients and 148 control subjects were included in the study. The characteristics of the whole cohort are summarised in [Table 1](#tbl1){ref-type="table"}. For 136 patients, tumours were classified as NMIBC (*T*\<2), whereas 16 patients were MIBC (T⩾2). Forty-one cases had grade G1 cancer, whereas 64 and 47 had G2 and G3 grade, respectively. Fifty-four cases were classified as high-risk, 45 as intermediate and 37 as low-risk.

CBMN end points at diagnosis
----------------------------

The 3 CBMN end points analysed, MN, NBUD and NPB, were not normally distributed (*P*=6.10 × 10e-09, *P*=3.40 × 10e-13 and *P*\<2.20 × 10e-16, respectively), therefore non-parametric tests were employed to verify differences among groups. Cytostasis, a biomarker of cell proliferation and mitogen responsiveness, was assessed by the nuclear division index via the ratio of mono-, bi- and multinucleated cells as described by [@bib16]). No differences among scorers and batches were observed (data not shown).

Overall, cases had a mean MN±standard deviation (s.d.) frequency of 9.51±4.73 compared with 7.73±3.91 of controls. The mean NBUD ±s.d. frequency in cases was 5.06±3.36 compared with 3.99±2.44 of controls. MN and NBUD frequencies were significantly higher in BC cases than in controls (Wilcoxon rank sum test, *P*=0.001 and *P*=0.006, respectively; [Table 2](#tbl2){ref-type="table"}, [Figure 1A and B](#fig1){ref-type="fig"}). When stratifying for the type of tumour and analysing only NMIBC, the differences in MN and NBUD frequencies among cases and controls were even more significant (*P*=0.0005 and *P*=0.002, respectively; [Table 2](#tbl2){ref-type="table"}, [Figure 1C and D](#fig1){ref-type="fig"}). For MIBC the MN frequency trend was similar although results were not statistically significant. No differences in CBMN end points were observed after stratification for grade, tumour stage, risk class or number of recurrences (data not shown).

In a logistic regression model adjusted for age and smoking similar results were obtained for MN and NBUD frequencies ([Table 3](#tbl3){ref-type="table"}). In particular, for each increase of one unit in the MN frequency a 1.11 increase of risk of developing BC (all cases *vs* controls) and a 1.12 for NMIBC cases were observed. Similar results were observed when testing NBUD frequencies (1.14 and 1.16 increase of risk, respectively).

MN, NBUD and NPB correlated each other but they did not correlate with smoking or age (data not shown). A significant decreased frequency of MN was found in current smokers when compared with never smokers both when considering all subjects (adjusted model for age and case-control status, *P*=0.03) or only cases (adjusted model for age, *P*=0.05). BC cases showed higher MN frequencies in all subgroups with different smoking habits, though only former smokers showed significant differences in MN and NBUD levels between cases and controls (*P*=0.003 and *P*=0.009, respectively; [Supplementary Figure 1A and B](#sup1){ref-type="supplementary-material"}); similarly, when considering only NMIBCs (for MN in former smokers: *P*=0.001; for NBUD in current and former smokers: *P*=0.04 and *P*=0.004, respectively; [Supplementary Figure 1C and D](#sup1){ref-type="supplementary-material"}). When smokers were stratified in heavy, moderate and light smokers according to their consume of cigarettes, the observed trends did not change. Light smokers had a slight, although not statistically significant, increase of MN frequency when compared with heavy smokers or to non-smokers (never and former smokers together; data not shown but available upon request).

CBMN assay in relation to clinical outcome
------------------------------------------

The information of patient follow up is briefly reported in [Table 1](#tbl1){ref-type="table"}. Most patients (105) were treated with either chemotherapy and/or Bacillus Calmette--Guerin (BCG) therapy. In total, 55 subjects recurred and 24 died. The mean (median) overall survival and event-free survival for patients were 54.5 (50.6) and 41.8 (35.7) months, respectively. Age and risk classification ([@bib3]; [@bib43]) were associated with overall survival (but not event-free survival) in the preliminary univariate assessment of covariates.

No significant associations with survival or recurrence risk were observed for any of the CBMN end points analysed (data not shown).

Genotype distribution in relation to case-control status and MN frequencies
---------------------------------------------------------------------------

A total of 783 SNPs in genes belonging to different pathways of DNA repair that remained after the quality control were analysed only in the largest group of NMIBC patients (*n*=132) and in controls (*n*=147). Genotypes frequencies of eight SNPs were differentially distributed between NMIBC and controls (*P*\<0.01; *χ*^2^ test) in a linear model adjusted for age and smoking habits ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). In particular, an increased risk for NMIBC cases was observed in carriers of the AG or GG genotype for rs804267 in *NEIL2* (*P*=0.02 and *P*=0.001, respectively) when compared with the AA genotype. A similar trend was observed for carriers of the AC or CC genotypes for *NEIL3* rs6817959 (*P*=0.0006 and *P*=0.01, respectively) when compared with the AA genotype. Conversely, having one or two variant alleles for rs7311151 in *RAD52* appeared to be protective when compared with the reference genotype AA (*P*=0.004 for the heterozygous and *P*=0.03 for the homozygous variant GG). The same observations were derived for carriers of TC and CC genotypes for *FANCL* rs11903456 (*P*=0.03 for both genotypes when compared with the wild type).

Ten SNPs were associated with significantly different MN frequencies according to the genotype stratification in NMIBC patients (*P*\<0.01; Kruskall--Wallis rank sum test; [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Five of these SNPs were in genes involved in homologous recombination pathway ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). No differences in MN frequencies according to a particular genotype were observed among controls for these 10 SNPs (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Interestingly, for *RAD51*B rs2257127, the MN frequencies in patients decreased according to the presence of 0, 1 or 2 variant alleles, whereas in controls this trend was the opposite, though significant only when comparing the homozygous subjects. Similar considerations could be done for rs1866074 in *TDG*, but in this case MN frequency increased in relation to the number of variant alleles. Notably, the observed differences were confirmed when applying an additive model of inheritance of the minor allele (data not shown). In a linear model controlling for age and smoking status, NMIBC patients carrying the TC or the CC genotypes of *XPC* rs2470458 showed a significant decrease of 2.29 and 4.78 units of MN, respectively, when compared with the most frequent TT genotype (*P*=0.01 and *P*=0.03). An opposite trend was found for rs976080 in *ERCC8* (increase of 3.31 MN units for CA carriers when compared with the reference; *P*=0.002). For rs1866074 in *TDG*, there was an increase in the frequencies of MN in carriers of AG and GG genotypes when compared with carriers of the reference genotype AA (increase of 2.43 and 4.05 units of MN; *P*=0.02 and *P*=0.001, respectively; [Figure 2](#fig2){ref-type="fig"}).

Other SNPs significantly modulating NBUD and NPB frequencies are reported in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}.

To evaluate the improvement in the performance of NMIBC case prediction when including genotype of DNA repair genes and MN frequencies, we analysed three nested models: model A=including age and smoking status; model B=model A+rs804267+rs6817959+rs11903456+rs7311151; model C=model B+MN frequencies. Comparing the area under ROC curve of the three models there was a statistically significant improvement in discrimination of NMIBC: in particular the area under ROC curves were 0.55, 0.75 and 0.79 for model A, B and C, respectively (model A *vs* model B: DeLong\'s *P*=2.80 × 10e-06; model B *vs* model C: DeLong\'s *P*=0.02; [Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

In the present study, the main result was an increased frequency of MN and NBUD in cryopreserved lymphocytes of BC cases assessed at diagnosis compared with controls, either considering all cases or, with an even more marked difference, the subgroup of NMIBC.

Several studies report an increased baseline frequency of MN and other CBMN end points in PBMC of cancer patients (reviewed by [@bib5]), confirming the presence of a high genetic instability in cancer. The majority of studies reported the presence of increased MN frequencies in individuals with cancer or with pre-neoplastic lesions. The number of studies performed on PBMC is quite high (8 studies on breast, 6 on lung, 2 on gastroenteric cancers and 13 on other malignancies). However, all these studies were mostly based on a small sample size. The only exceptions are represented by the study of [@bib14]), performed on PBMC from 197 controls and 57 head-and-neck cancer patients, and the one of [@bib15]), on lymphocytes from 139 lung cancer cases and 130 controls. Thus, our study is the largest study so far on BC patients.

The CBMN assay measures chromosomal DNA damage, cytostasis and cytotoxicity events in the cell population ([@bib16]). It is generally accepted that events of genetic damage such as MN and NBUD may represent a reflection of misrepaired DNA breaks, dysregulation on telomere length as well as malfunctions in the mitotic machinery and DNA amplification ([@bib18]). An increase in MN frequency may be considered a biomarker of chromosome loss and/or breakage, whereas other anomalies such as NBUD are biomarkers of gene amplification and/or removal of unresolved DNA repair complexes ([@bib5]). In cancer, an increase of various manifestations of chromosomal instability is often observed. Assuming that the induction of chromosomal damage employs similar mechanisms in different tissues, the levels of damage measured in lymphocytes and other surrogate tissues may reflect those present in the cancer-prone tissues ([@bib5]; [@bib34]).

Constitutive DNA damage in cells can be considered a predictive biomarker indicating a potential increase in cancer risk. The thresholds of tolerable DNA/chromosomal damage are known for small eukaryotic organisms such as *Saccharomyces cerevisiae*, but little is known for human cells ([@bib22]). An increase in MN frequency in PBMC of BC cases when compared with controls could be interpreted as an altered status in the DNA damage repair system or reflects an unknown past exposure. These lead to the accumulation of chromosomal damage promoting malignant transformation. However, there is no common agreement on that and an altered DNA repair system could be also a direct effect in the organism of the presence of the tumour ([@bib39]). A better understanding of the level of systemic DNA damage in cancer patients may help in a more precise use of therapeutic intervention. For example, a better definition for the minimum threshold of DNA/chromosomal damage that kills tumour cells directly or reactivates mechanisms of tumour-suppression can help in choosing a more effective chemo- or radiotherapy dosage ([@bib22]).

Several factors may modulate the MN formation and frequency. Lifestyle habits (smoking, alcohol, vitamin intake) and host factors (age, gender) are among them, as well as genetic polymorphisms and exposure to specific mutagen agents ([@bib25]). Notably, we observed a significant decrease in MN frequency in current smokers when compared with non-smokers (both considering all subjects and only cases). This is in line with previous investigations on the impact of smoking on MN levels, in which the MN rates are higher in non-smokers than in smokers (reviewed by [@bib28])). The reduction of MN levels in smokers reported in literature is usually present only in light and moderate smokers, whereas heavy smokers have higher levels of MN when also occupational exposure is taken into account ([@bib6]). In our study we did not observe this phenomenon after categorisation according to the consume of cigarettes. This is probably due to the fact that the number of smokers is too small to observe an effect of smoke on MN frequencies as reported in other studies. Interestingly, smoking or formerly smoking BC patients had still higher levels of chromosomal damage than controls and the observed effect of smoking could be due to a constitutively activated antioxidant response system or an active DNA repair. The question on the effect of smoking on MN frequencies is still open and results in literature are controversial ([@bib28]).

Knowing a patient\'s basal genetic background and consequently the individual DNA repair capacity is important for predicting BC risk. Genetic variants in DNA repair genes that could modify BC risk and prognosis has already been identified in various studies, including polymorphisms in *XRCC1*, *XRCC4*, *XPF*, *XPD* and *XPC* ([@bib40]; [@bib20]; [@bib29]). Among the eight SNPs significantly associated with NMIBC risk in the present study, *NEIL2* rs804267 has been associated in another study with risk of recurrence/progression in 421 NMIBC patients, particularly in those receiving BCG therapy ([@bib42]). Conversely, rs25487 in *XRCC1* was associated with decreased risk of BC in the present study and in a previous one performed on 227 Chinese BC patients and 260 controls ([@bib44]). The functional significance of *XPC* rs2470458 is still unclear. *XPC* rs2470458 has been indicated as an important and independent predictor for survival of melanoma patients ([@bib24]). In a previous study, the presence of the variant allele of rs2228000 (in linkage disequilibrium with rs2470458), which causes a Val499Ala amino acid change, modulated expression levels of *XPC, XPB* and *XPD* genes in colorectal cancer patients ([@bib35]). In particular, rs2228000 is well-known to contribute to the susceptibility to BC in Caucasian populations ([@bib41]). Finally, BC patients carrying the GG genotype of rs1866074 resulted at decreased risk of disease progression ([@bib42]). Although the effect of a single SNP on BC risk may be limited, the combined effect of several SNPs in the same or different genes could be more significant. Interestingly, tagging SNPs selected across the entire coding and putative regulatory regions of *ERCC8* (known as *CSA*) were associated with mutagen sensitivity induced by BPDE in 276 cancer-free smokers as measured with the comet assay ([@bib23]).

In a review by Fenech and collaborators, a detailed nutrient-gene interaction model involving various molecular mechanisms has been reported. In this model, the interaction between a specific polymorphism in *MTHFR*, folate and riboflavin deficiency in the diet lead to MN, NPB and NBUD formation as a consequence of derived chromosomal instability through several molecular mechanisms. Analogous models could be plausibly extended to other pathways such as DNA repair ([@bib18]). MN formation derives from genetic defects in cell cycle checkpoints and/or DNA repair genes, therefore, genetic variations in such genes may also affect the levels of chromosome damage by ultimately modulating the individual DNA repair activity ([@bib21]). Specific genotypes of polymorphisms in DNA repair genes such as *XPD*, *XRCC1* and *XRCC3* were previously associated with increased MN frequencies in workers exposed to ionising radiation ([@bib1]). In the present study, we evaluated MN frequencies in NMIBC cases in relation to a large number of polymorphisms in DNA repair genes, investigated at GWAS level. Among the 10 SNPs associated with different MN frequencies according to the genotype stratification, three of them (rs2470458 in *XPC*, rs1866074 in *TDG* and rs976080 in *ERCC8*) resulted in significant associations also in the linear model. For the polymorphism in *XPC* a decrease in the MN frequency was observed in variant allele carriers when compared with the reference genotypes. For *TDG* rs1866074, there was an increase in the frequencies of MN in carriers of AG and GG genotypes when compared with carriers of the reference genotype AA. A similar observation was done for carriers of the CA genotype in *ERCC8* rs976080, although in the present study there were no AA homozygotes. It seems that the presence of a single A allele for this SNP is sufficient to have a significant increase in the MN frequency. Interestingly, among the 10 SNPs altering MN frequency in NMIBC there was an overrepresentation of polymorphisms in genes involved in the homologous recombination pathway (5 out of 10; *XRCC3* rs861539, *SHFM1* rs12704871, *RAD51B* rs2257127, *PARP1* rs3754376 and rs1136410), which is supposed to be the main DNA repair pathway involved in the control of chromosome stability ([@bib32]), and whose subtle inter-individual differences may be connected to altered MN frequencies.

We are aware of some weaknesses of the present study. The CBMN assay is a highly sensitive method to evaluate the action of genotoxic agents, which may trigger the cascade of events leading to BC onset. However, in a cross-sectional study like the present one, this test does not provide any insight as to whether the observed chromosomal damage is a cause or a consequence of some exposure/presence of the disease. Moreover, human lymphocytes are usually used for measuring genotoxic effects induced by various mutagens in human biomonitoring studies, but the sensitivity of MN end points may be limited by the repair of DNA damage during PHA-stimulated lymphocytes culture. On the other hand, previous studies have demonstrated that there are no differences in DNA damage and repair capacity between unstimulated and PHA-stimulated lymphocytes even after 72 h of culture ([@bib4]).

A recent review reported all the studies applying the MN assay in urine-derived cells (UDC) as a diagnostic tool for BC detection and prognosis ([@bib28]). To our knowledge, only few studies investigated if the MN assay could be applied as a diagnostic tool to identify individuals who have BC ([@bib2]; [@bib33]; [@bib12]). The currently available data suggested that MN assays in UDC may be potentially a suitable diagnostic tool for detection of BC and for the surveillance of the patients ([@bib28]). The specificity and sensitivity of the assay on UDC has to be further validated in large studies. The available studies, in fact, are restricted to a small number of subjects (\<50 subjects) highlighting that for large studies it could be difficult to process a large number of fresh urine samples. Although urine could be potentially a better specimen for the study of BC risk rather than PBMC, it should be considered that the MN assay applied to UDC presents still some limitations. UDC extraction needs in fact to be performed on fresh urine to ensure viable cells. Moreover, the proportion of live cells extracted from urine is very low so sometimes it is not possible to score enough cells.

In theory, employing fresh blood is more advantageous from the practical point of view, since with small blood amounts it is possible to obtain good cells proliferation after mitogen stimulation. However, there are some drawbacks that limit its use in human cytogenetic studies. It is in fact quite difficult to process hundreds of samples in a short time as requested in large studies. Moreover, it has been demonstrated that to arrange the blood collection over a long-time interval may increase the experimental variability due to seasonal variation ([@bib45]). These limitations can potentially be overcome by employing cryopreserved cells. The use of these cells may allow a better study planning with *a priori* selection of subjects of interest and the possibility to data recovery in case of lost samples. Cryopreserved PBMC have been successfully used before for measuring endogenous DNA damage and/or DNA repair capacity by different assays ([@bib11]; [@bib9]), but also for MN analysis with cytokinesis-block ([@bib45]) bringing significant advantages in biomonitoring and for biomarkers research.

In conclusion, the observed increase in MN and NBUD frequencies in BC cases could be used to better estimate individual BC risk, including in the same model classical risk factors and DNA repair genetic susceptibility variants. Understanding the level of systemic chromosomal damage in cancer patients may also help in more precise therapeutic intervention.
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![**Box plot for comparison of MN and NBUD frequencies in different study groups: MN frequencies in** (**A**) BC cases *vs* controls and (**C**) in NMIBC cases *vs* controls; NBUD frequencies in (**B**) BC cases *vs* controls and (**D**) in NMIBC cases *vs* controls.](bjc2016411f1){#fig1}

![**MN frequencies in NMIBC** patients (*n*=132) according to genotype distribution of selected SNPs in DNA repair genes (Kruskal--Wallis *P*\<0.01).](bjc2016411f2){#fig2}

![**ROC curve analysis for discrimination of NMIBC.** Model A investigated the risk reached by adding age and smoking habit; model B included also the SNPs differentially distributed among cases and controls (model A+rs804267+ rs6817959+rs11903456+rs7311151); model C included model B and MN frequencies.](bjc2016411f3){#fig3}

###### Baseline characteristics of the BC patients and information at follow up

  **Covariates**                                     **Cases (%)**   **Controls (%)**
  ------------------------------------------------- --------------- ------------------
  *N*                                                     152              148
  NMIBC                                               136 (89.5)            --
  MIBC                                                 16 (10.5)            --
  Age (years)                                                                
   Mean±s.d.                                           62.3±7.9          62.8±8.7
   Range                                              40.0--74.1        40.3--74.9
  Smoking Status                                                             
   Never                                               21 (13.8)        24 (16.2)
   Former                                              94 (61.8)        90 (60.8)
   Current                                             37 (24.4)        34 (23.0)
  T stage[a](#t1-fn2){ref-type="fn"}                                         
   Ta                                                  84 (55.3)            --
   T1                                                  46 (30.3)            --
   T2                                                  14 (9.2)             --
   T3                                                   1 (0.7)             --
   T4                                                   1 (0.7)             --
   Tis                                                  3 (1.9)             --
   Tx                                                   3 (1.9)             --
  Grading (1973)[a](#t1-fn2){ref-type="fn"}                                  
   G1                                                  41 (27.0)            --
   G2                                                  64 (42.1)            --
   G3                                                  47 (30.9)            --
  Grading (2004)[a](#t1-fn2){ref-type="fn"}                                  
   Non-high grade                                      77 (50.7)            --
   High grade                                          75 (49.3)            --
  Risk[a](#t1-fn2){ref-type="fn"}                                            
   Low-risk                                            37 (24.4)            --
   Intermediate Risk                                   45 (29.6)            --
   High-risk                                           54 (35.5)            --
   Muscle invasive                                     16 (10.5)             
  Recurrence                                                                 
   No                                                  97 (63.8)            --
   Yes                                                 55 (36.2)            --
  Number of recurrences                                                      
   1                                                   35 (63.6)            --
   2                                                   15 (27.3)            --
   ⩾3                                                   5 (9.1)             --
  Progression                                                                
   No                                                 146 (96.1)            --
   Yes                                                  6 (3.9)             --
  Therapy                                                                    
   No                                                  47 (30.9)            --
   Yes                                                105 (69.1)            --
  Cystectomy                                                                 
   No                                                 125 (82.2)            --
   Yes                                                 27 (17.8)            --
  BC patient DiacriticalGrave status at follow up                            
   Alive                                              128 (84.2)            --
   Died                                                24 (15.8)             
   Of which for BC                                        11                --

Abbreviations: BC=bladder cancer; MIBC=muscle-invasive bladder cancer; NMIBC=non-muscle invasive bladder cancer.

For reference see: (1) [@bib3]; (2) [@bib10]; (3) [@bib27].

###### Frequencies of analysed end points by the CBMN assay in peripheral blood mononuclear cells of BC cases and healthy controls

                     **Controls**   **All BC Cases**    ***P***[b](#t2-fn4){ref-type="fn"}  **NMIBC**    ***P***[b](#t2-fn4){ref-type="fn"}  **MIBC**    ***P***[b](#t2-fn4){ref-type="fn"}
  ------ ----------- -------------- ------------------ ------------------------------------ ----------- ------------------------------------ ----------- ------------------------------------
  MN      Mean±s.d.  7.73±3.91      9.51±4.73                       **0.001**               9.68±4.77                **0.0005**              8.06±4.24   0.91
  NPB     Mean±s.d.  0.88±0.90      0.98±1.03                          0.61                 0.99±1.03                   0.55                 0.88±1.09   0.85
  NBUD    Mean±s.d.  3.99±2.44      5.06±3.36                       **0.006**               5.20±3.41                **0.002**               3.87±2.69   0.65

Abbreviations: BC=bladder cancer; MIBC=muscle-invasive bladder cancer; MN=micronuclei; NBUD=nuclear buds; NMIBC=non-muscle invasive bladder cancer; NPB=nucleoplasmic bridge.

Significant results in bold.

Mean frequencies for 1000 binucleated cells.

Wilcoxon Rank sum test.

###### Logistic regression model of analysed end points by the CBMN assay for: (A) BC *vs* controls; (B) NMIBC *vs* controls; (C) MIBC *vs* controls

                        **Coefficients**   **s.e.**    ***P***[a](#t3-fn3){ref-type="fn"}
  --------------------- ------------------ ---------- ------------------------------------
  MN                                                  
  BC *vs* controls      0.104              0.029                   **\<0.01**
  NMIBC *vs* controls   0.114              0.030                   **\<0.01**
  MIBC *vs* controls    0.011              0.069                      0.87
  NPB                                                 
  BC *vs* controls      0.115              0.121                      0.34
  NMIBC *vs* controls   0.130              0.125                      0.30
  MIBC *vs* controls    −0.016             0.292                      0.96
  NBUD                                                
  BC *vs* controls      0.132              0.043                   **\<0.01**
  NMIBC *vs* controls   0.148              0.045                   **\<0.01**
  MIBC *vs* controls    −0.037             0.112                      0.74

Abbreviations: BC=bladder cancer; MIBC=muscle-invasive bladder cancer; MN=micronuclei frequencies; NBUD=nuclear buds frequencies; NMIBC=Non-muscle invasive bladder cancer; NPB=nucleoplasmic bridge frequencies; s.e.=standard error.

Significant results in bold.

Adjusted for age and smoking.

[^1]: These authors contributed equally to this work.
